Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for HYDREA
- Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
- Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts
- Management of Severe Acute Malnutrition in SCD, in Northern Nigeria
- Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMT CTN 1507)
- Moderate Dose Hydroxyurea for Secondary Stroke Prevention in Children With Sickle Cell Disease in Sub-Saharan Africa
- Primary Prevention of Stroke in Children With SCD in Sub-Saharan Africa II
- Treatment of Hemoglobin SC Disease With Hydroxyurea
- Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer
- Risk-based Therapy for Sickle Cell Anemia: A Feasibility Study
- Realizing Effectiveness Across Continents With Hydroxyurea (REACH)
- Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma
- Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
- Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer
- Sickle Cell Disease - Stroke Prevention in Nigeria Trial
- Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer
- Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE)
- Pharmacokinetics (PK) of Liquid Hydroxyurea in Pediatric Patients With Sickle Cell Anemia
- Transcranial Doppler (TCD) With Transfusions Changing to Hydroxyurea
- Hydroxyurea to Prevent Brain Injury in Sickle Cell Disease
- A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms
- Decitabine in Patients With Chronic Myelomonocytic Leukemia (CMML)
- Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma
- Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma
- Evaluating the Safety of G-CSF Mobilization in Individuals With Beta Thalassemia Major
- 2NN & CHARM Long-Term Follow-up Study
- Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer
Clinical trials list
click for details